Literature DB >> 28975380

Immunological classification of renal cell carcinoma patients based on phenotypic analysis of immune check-point molecules.

Atsunari Kawashima1,2, Takayuki Kanazawa3,4, Kumiko Goto5,6, Mitsunobu Matsumoto5,6, Akiko Morimoto-Okazawa5, Kota Iwahori5, Takeshi Ujike7, Akira Nagahara7, Kazutoshi Fujita7, Motohide Uemura7, Norio Nonomura7, Hisashi Wada5.   

Abstract

OBJECTIVES: To clarify comprehensive immunological signature patterns of tumour tissue-infiltrating lymphocytes in patients with renal cell carcinoma and show its clinical significance.
MATERIALS AND METHODS: We investigated the surface marker expressions of tumour tissue-infiltrating lymphocytes quantitatively and classified them based on their functional populations. We extracted 109 sets of tumour tissue-infiltrating lymphocytes from 80 patients who underwent surgical resection of renal cell carcinoma, of which 44 tumour tissue-infiltrating lymphocytes were multiply extracted from 15 patients. Each tumour tissue-infiltrating lymphocyte was characterised on the basis of functional T-cell populations using ten surface marker expressions measured by flow cytometry.
RESULTS: All sets of the tumour tissue-infiltrating lymphocytes were classified into three groups, which correlated significantly with Fuhrman grade (OR 0.253, 95% CI 0.094-0.678, P = 0.006). Importantly, both overall metastasis-free survival (HR 0.449, 95% CI 0.243-0.832, P = 0.011) and recurrence-free survival (HR 0.475, 95% CI 0.238-0.948, P = 0.035) of the patients with the higher marker expressions were significantly inferior to those of the patients with the lower marker expressions by multivariate analysis. Six specific genes for this classification identified by microarray analysis verified our results using the TCGA KIRC data set. In addition, we discovered the presence of intra-tumoural diversity in the classification of 3 (20%) of the 15 patients.
CONCLUSIONS: This study showed that the presence of classable diversity in the immunological signature of tumour tissue-infiltrating lymphocytes correlated with prognosis and tumour aggressiveness that was observed even within individual tumours in some patients with renal cell carcinoma.

Entities:  

Keywords:  Heterogeneity; Hot cluster; Immunological classification; Intra-tumour diversity; PD-1; Tim-3

Mesh:

Substances:

Year:  2017        PMID: 28975380     DOI: 10.1007/s00262-017-2060-5

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  8 in total

Review 1.  Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines.

Authors:  Dixita Ishani Viswanath; Hsuan-Chen Liu; David P Huston; Corrine Ying Xuan Chua; Alessandro Grattoni
Journal:  Biomaterials       Date:  2021-11-30       Impact factor: 12.479

2.  Tumor-infiltrating CD8+ T cells recognize a heterogeneously expressed functional neoantigen in clear cell renal cell carcinoma.

Authors:  Masahiro Matsuki; Yoshihiko Hirohashi; Munehide Nakatsugawa; Aiko Murai; Terufumi Kubo; Shinichi Hashimoto; Serina Tokita; Kenji Murata; Takayuki Kanaseki; Tomohide Tsukahara; Sachiyo Nishida; Toshiaki Tanaka; Hiroshi Kitamura; Naoya Masumori; Toshihiko Torigoe
Journal:  Cancer Immunol Immunother       Date:  2021-09-07       Impact factor: 6.968

3.  Tumour grade significantly correlates with total dysfunction of tumour tissue-infiltrating lymphocytes in renal cell carcinoma.

Authors:  Atsunari Kawashima; Takayuki Kanazawa; Yujiro Kidani; Tetsuya Yoshida; Michinari Hirata; Kentaro Nishida; Satoshi Nojima; Yoshiyuki Yamamoto; Taigo Kato; Koji Hatano; Takeshi Ujike; Akira Nagahara; Kazutoshi Fujita; Akiko Morimoto-Okazawa; Kota Iwahori; Motohide Uemura; Ryoichi Imamura; Naganari Ohkura; Eiichi Morii; Shimon Sakaguchi; Hisashi Wada; Norio Nonomura
Journal:  Sci Rep       Date:  2020-04-10       Impact factor: 4.379

4.  Integration of intratumoral RASSF10 expression and tumor-associated macrophages into the established clinical indicators better predicts the prognosis of clear cell renal cell carcinoma patients.

Authors:  Chao Wang; Tianyu Hong; Yuning Wang; Sishun Gan; Qifeng Wang; Jian Li; Li Zuo; Xingang Cui
Journal:  Oncoimmunology       Date:  2020-03-11       Impact factor: 8.110

5.  T cells expanded from renal cell carcinoma display tumor-specific CD137 expression but lack significant IFN-γ, TNF-α or IL-2 production.

Authors:  Saskia D van Asten; Rosa de Groot; Marleen M van Loenen; Suzanne M Castenmiller; Jeroen de Jong; Kim Monkhorst; John B A G Haanen; Derk Amsen; Axel Bex; Robbert M Spaapen; Monika C Wolkers
Journal:  Oncoimmunology       Date:  2021-01-21       Impact factor: 8.110

6.  Immune Cell Infiltration-Based Characterization of Triple-Negative Breast Cancer Predicts Prognosis and Chemotherapy Response Markers.

Authors:  Yufei Lv; Dongxu Lv; Xiaohong Lv; Ping Xing; Jianguo Zhang; Yafang Zhang
Journal:  Front Genet       Date:  2021-03-19       Impact factor: 4.599

7.  Development and validation of a PBRM1-associated immune prognostic model for clear cell renal cell carcinoma.

Authors:  Jiayi Chen; Chunlin Yao; Nan Qiao; Yangyang Ge; Jianhua Li; Yun Lin; Shanglong Yao
Journal:  Cancer Med       Date:  2021-09-18       Impact factor: 4.452

8.  Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients.

Authors:  Qinchuan Wang; Jinhua Zhang; Huakang Tu; Dong Liang; David W Chang; Yuanqing Ye; Xifeng Wu
Journal:  J Immunother Cancer       Date:  2019-11-29       Impact factor: 13.751

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.